-
MSD commences Phase III trial of DLBCL treatment
07 Feb 2025 18:40 GMT
… -010 trial to assess its investigational antibody-drug conjugate … (R-CHP), to treat individuals with previously untreated … the end of the treatment.
MSD Research Laboratories oncology … most widespread form of non-Hodgkin lymphoma (NHL), DLBCL accounts …
-
Non-Hodgkin's Lymphoma Clinical Trial Pipeline | 200+ Companies Driving Innovation to Transform Treatment
07 Feb 2025 16:47 GMT
… Non-Hodgkin's Lymphoma therapies in various stages of clinical development. Major pharmaceutical … develop 220+ pipeline drugs for Non-Hodgkin's Lymphoma treatment.
• The leading Non-Hodgkin … more about Non-Hodgkin's Lymphoma medication @ https:…
-
MSD starts pivotal trial of ROR1 drug in first-line lymphoma
07 Feb 2025 14:06 GMT
… trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment … DLBCL), cementing the antibody-drug conjugate's position … this common form of non-Hodgkin lymphoma (NHL).
Zilo-V … anti-ROR1 drugs coming through development, along with CStone Pharma';s …
-
Merck initiates phase 3 waveLINE-010 trial Initiation of zilovertamab vedotin, an investigational ADC to treat patients with previously untreated DLBCL
07 Feb 2025 09:20 GMT
… Merck’s investigational antibody-drug conjugate (ADC) that … to the current standard treatment,” said Dr. Gregory Lubiniecki … non-Hodgkin lymphoma.”
WaveLINE-010 is a randomized, open-label phase 3 trial … has a broad clinical development program that evaluates …
-
Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
06 Feb 2025 11:56 GMT
… to the current standard treatment,” said Dr. Gregory … non-Hodgkin lymphoma.”
WaveLINE-010 is a randomized, open-label Phase 3 trial … the impact of pharmaceutical industry regulation and … inherent in new product development, including obtaining regulatory …
-
FDA Grants ADI-001 Fast Track Designation as Treatment of Refractory Systemic Lupus Erythematosus
06 Feb 2025 01:04 GMT
… treatment of a variety of autoimmune diseases.
Previously, the drug … from our study in non-Hodgkin lymphoma demonstrating robust … Symptoms of lupus typically develop slowly, and can include … impress your pharmacy colleagues with the latest drug information, …
-
FDA-Approved Calquence Combo Is First and Only of Its Kind in MCL
05 Feb 2025 21:13 GMT
… and Drug Administration (FDA) granted traditional approval to treatment with Calquence … typically aggressive form of non-Hodgkin lymphoma (NHL), which … knowledge of these two drugs with the physician and … of the ECHO trial, according to the FDA website. The …
-
Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20
05 Feb 2025 13:00 GMT
… its upcoming combination trial, which pairs Decoy20 … improve treatment outcomes for patients facing difficult-to-treat cancers … carcinomas, pancreatic and non-Hodgkin’s lymphomas in standard … product candidates during clinical development; our ability to …
-
Govt Approves Qartemi, A Living Drug For Destroying Cancer Cells
04 Feb 2025 23:01 GMT
… or relapsed B-cell Non-Hodgkin Lymphoma (B-NHL). Developed by Immuneel Therapeutics … traditional chemical drugs, are known as “living drugs.” These personalized treatments involve extracting … to FDA-approved CAR-T therapies, with the Phase 2 trial achieving …
-
TAK-007 Shows Favorable Safety, Early Efficacy Data in R/R B-Cell Non-Hodgkin Lymphoma
04 Feb 2025 22:50 GMT
… #47;refractory B-cell non-Hodgkin lymphoma (NHL), according to … future exploration.”
Regarding safety, treatment-emergent adverse effects (TEAEs) … .
Additional Safety and Pharmacokinetic Data
In the overall … not associated with the development of CRS, ICANS, …
About
© 1995-2025